Eli Lilly's new medication approved by the FDA could change the lives of the 39 million Americans suffering from migraines. The treatment, being marketed under the brand name Emgality, will be a once a month dosing that will help patients cut the frequency of their migraines in half, said president of Lilly Bio-Medicines Christi Shaw in an interview with Cheddar.